REDWOOD CITY, Calif., Nov. 3, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that the Company has been awarded a total of $488,958 in grants under the Qualifying Therapeutic Discovery Project (“QTDP”) program to advance the development of clinical programs for TH-302, the Company’s hypoxia activated prodrug. The Company submitted applications for its clinical program studying TH-302 for the treatment of cancer and for its hypoxia-activated prodrug technology platform for drug discovery. The maximum grant allowable under the QTDP program in the amount of $244,479 was approved for each project.
